Modeling Human Gamma Delta T Cells as Antitumor Agents In Vivo
Abstract
The central objective of this project is to provide mechanistic data that will support the development of human Vgamma9Vdelta2 T cells as an anti-tumor cellular immunotherapy for lymphomas driven by Epstein-Barr virus (EBV) infection. During this research period we have completed the following: i) Obtained local IRB and ACUC approvals and obtained HRPO and ACURO approval; ii) obtained adult human peripheral blood cells, expanded Vgamma9Vdelta2 T cells, sorted to obtain high-purity preparations, generated frozen stocks and confirmed viability upon thaw; iii) generated viral stocks and performed in vivo dose-response experiments to determine appropriate dosing for lymphoma formation; iv) initiated analyses to identify an appropriate BTN3A1 blocking mAb; v) resolved technical issues that caused lysis of cord blood cells prior to injection into immune-deficient mice and failure of the human immune cells to successfully engraft after injection. We are thus now in a position where we will be able to move forward with performing the proposed mechanistic experiments.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2018
- Accession Number
- AD1060431
Entities
People
- Jenny E. Gumperz
Organizations
- University of Wisconsin–Madison